Fundraising FoxContinuity Biosciences
Bradenton, US · Founded 2023 · Delaware LLC · 1 known investors
Find your way into Continuity Biosciences
Sign up to see every warm intro you have to Continuity Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Continuity Biosciences team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Continuity Biosciences develops adaptive precision drug-delivery platforms that combine engineering and biology to help therapies reach their intended targets more effectively. The company works across multiple therapeutic applications rather than a single drug or disease, bridging medtech and biotech.
Founders & leadership
Continuity Biosciences was founded in 2023 by Ramakrishna Venugopalan.
RV
Ramakrishna VenugopalanCo-Founder & Chief Executive Officer
RW
Robert WhiteheadCo-Founder & Executive Chair
Board
AG
Alessandro GrattoniChief Scientific Advisor
Investors · 1
Reported raises · per SEC filings
Form D private placements$11.9M disclosed across 3 rounds · 2024–2025
▶$8.4MraisedAug 2025 · 13 investors · BiotechnologyRule 506(b)
▶$8.4MraisedAug 2025 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael L. FowlerDirector
- Allen R. WeissDirector
- Monica P. ReedDirector
- Joseph DeSimoneDirector
- Ramakrishna VenugopalanExecutive Officer, Director
- Robert WhiteheadDirector
- Josephine TorrenteDirector
- Offering amount
- $12M
- Amount sold
- $8.4M
- First sale
- Aug 2025
- Incorporated
- Limited Liability Company, Delaware, 2023
- Federal exemptions
- 06b
▶$1MraisedJun 2025 · 13 investors · BiotechnologyRule 506(b)
▶$1MraisedJun 2025 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ramakrishna VenugopalanExecutive Officer, Director
- Robert WhiteheadDirector
- Allen R. WeissDirector
- Michael L. FowlerDirector
- Monica P. ReedDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- May 2025
- Incorporated
- Limited Liability Company, Delaware, 2023
- Federal exemptions
- 06b
▶$2.5MraisedJul 2024 · 10 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJul 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert WhiteheadExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $2.5M
- First sale
- Jun 2024
- Incorporated
- Limited Liability Company, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Precision BioSciencesPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Life BiosciencesLife Biosciences is a biopharmaceutical company developing therapies focused on aging and age-related diseases, working across gene therapy and neuroscience programs. It advances drug candidates from discovery through clinical development.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Intuitive BiosciencesIntuitive Bio develops Colony Surveillance Assays (CSA), diagnostic kits for screening laboratory animal colonies for exposure to specific pathogens. The kits are designed for research institutions and breeding facilities requiring pathogen-free colony verification.
Solid BiosciencesSolid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.
Companies working in the same space as Continuity Biosciences.
Frequently asked questions
- What does Continuity Biosciences do?
- Continuity Biosciences develops adaptive precision drug-delivery platforms that combine engineering and biology to help therapies reach their intended targets more effectively. The company works across multiple therapeutic applications rather than a single drug or disease, bridging medtech and biotech.
- Who founded Continuity Biosciences?
- Continuity Biosciences was founded by Ramakrishna Venugopalan in 2023.
- Who are Continuity Biosciences's investors?
- Continuity Biosciences's investors include MERGING TRAFFIC.
- How much funding has Continuity Biosciences raised?
- Continuity Biosciences has disclosed $11.9M raised across 3 rounds.
- Where is Continuity Biosciences headquartered?
- Continuity Biosciences is headquartered in Bradenton, US.